No Data
CStone Pharmaceuticals Schedules Board Meeting to Approve 2024 Annual Results
CSTONE PHARMA-B: DATE OF BOARD MEETING
CSTONE PHARMA-B (02616): Advancing towards Pipeline 2.0, with significant potential for ROR1 ADC.
Cornerstone Pharmaceuticals is an innovative, research-driven Biomedical company focused on the R&D of anti-tumor drugs. As of February 2025, the company has successfully launched 4 Innovative Drugs and obtained approval for 16 new drug marketing applications (NDA and 9 indications).
Express News | CStone Submits Clinical Trial Application in Australia for Cs5001 (Ror1 ADC) in Combination With First-Line Standard-of-Care for Dlbcl
CSTONE PHARMA-B (02616.HK) submitted a clinical trial application in Australia for CS5001 (ROR1 ADC) in combination with standard treatment for first-line DLBCL.
On March 6, Glorious Finance reported that CSTONE PHARMA-B (02616.HK) announced it has successfully submitted an application for an Ib phase clinical trial in Australia for CS5001 (ROR1 ADC) combined with standard treatment for frontline diffuse large B-cell lymphoma (DLBCL). In addition, a global multicenter clinical trial of CS5001 as a monotherapy and in combination with PD-L1 monoclonal antibody for advanced solid tumors is also ongoing. This Ib phase clinical trial further expands on the data from CS5001 monotherapy treatment for refractory and indolent advanced lymphoma, aiming to explore ROR1 ADC in depth.
Express News | CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of Cs2009, a Pd-1/Vegf/Ctla-4 Trispecific Antibody
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
